



Welcome

**Virtual Governance Meetings
Strategic Sessions**

22 and 24/25 June 2021

Trusted evidence.
Informed decisions.
Better health.



Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Cochrane's strategic challenges & opportunities

Tracey Howe & Catherine Marshall
Co-Chairs, Governing Board

Judith Brodie
Interim Chief Executive Officer

Karla Soares-Weiser
Editor in Chief

Question & Answers
Audience



Tracey Howe & Catherine Marshall

“Tomorrow, tomorrow,
I love ya tomorrow,
You’re always
a day away...”



Aims of today

- To provide an opportunity to **reconnect** and **network**
- To **share** the challenges and opportunities for Cochrane
- To harness the **collective brain power** of our global community by **listening** to your views, thoughts and ideas - everyone's views matter
- To introduce **Judith Brodie**, our new Interim Chief Executive Officer

How you can participate:

- Add your **questions and thoughts** in the 'Q&A channel' here
- Answer the **online polls** coming up
- Attend the **breakout sessions**

Why was Cochrane established?

Archie Cochrane:

- Identified need to **inform decisions**
- Understood the issues created by **continuous growth of research**
- Called for **up-to-date, systematic reviews** of all relevant randomised controlled trials in the field of healthcare

Cochrane's founding members:

- Concerned about **doing more harm than good** in clinical practice
- Identified need for **creative efforts** to meet the needs of fellow clinicians and patients
- Cochrane Collaboration established 1993

“Necessity is the mother of invention”

Proverb

Our beneficiaries



PUBLIC, PATIENTS,
AND CARERS



HEALTH AND CARE
WORKERS



RESEARCHERS



POLICY AND
GUIDELINE
DEVELOPERS


Our members and supporters contribute



TIME (PROXY FOR
MONEY)



ENTHUSIASM



KNOWLEDGE AND
IDEAS



ATTENTION FROM
OTHER THINGS IN
THEIR LIFE

Amazing growth of Cochrane



Global context



- Ageing population and global population growth
- Migration
- Huge socio-economic inequalities
- Impact of climate change: food shortages, destructive weather patterns, political unrest and conflicts

Increased focus on:

- Inequality and exclusion – #MeToo, Black Lives Matter, LGBT*IQ and rainbow issues, importance of indigenous people's rights, dis-ability, and mental health
- UN Sustainable Development Goals
- Smart phones, internet, social media, AI, smart technology, digital medicine
- New ways of learning and sharing knowledge

**“Change is inevitable
....change is constant”**

Benjamin Disraeli 1867

What new challenges & opportunities have been created for Cochrane by world events of the past 18 months?

Views of Cochrane Groups and members collated and analyzed by the Cochrane Council

Virtual Governance Meetings 2021: Council response

10 June 2021

In this collated report we focus on the commonalities among the different constituencies. We appreciate that each group type (review, methods, geographic, fields) has a different focus and area of expertise and therefore each Executive's feedback is of high value. These views are reported in the table produced by the CET.

Overall, common concerns and opinions emerged from the Executives, each one influenced by its own perspective:

- Concerns about funding linked to Open Access and potential NIHR funding changes for UK CRGs.
- The plan for re-organization, increased centralized control of review production and new and better defined standards.
- The struggle to find the right balance between:
 - internal (our values) versus external (funders, but also others) needs;
 - Speed of production and rigour of methods;
 - Common centralized processes to level-up quality and standards versus diffused organization to increase reach-out and facilitate contacts;
 - Voluntary work and professionalism;
 - Evidence production and knowledge translation;
 - Complexity of content versus ease of use/accessibility.

1. What new challenges and opportunities have been created for Cochrane by world events of the past 18 months?


Challenges	Opportunities
1.1.1 Review production	
<ul style="list-style-type: none">• Reduced support to CRGs.• Cumbersome processes with centralised editorial functions on top of CRG and Network layers.• Easy access to enough specialist methodologists.• Availability of multiple and trusted sources.• Multiple evidence syntheses addressing ostensibly the same questions (e.g. multiple NMAs on the same	<ul style="list-style-type: none">• Recognition of the importance of evidence synthesis.• Open Access allowed Cochrane evidence to be available and accessible.• Expand beyond standard intervention reviews and RCTs/CCTs.• We need to cover areas where there are no RCTs with the best evidence available.

Communication

Keep it simple - summarizing our work in language and formats that are easily accessible and understandable. We need to innovate.

“The Internet has changed the way we communicate with each other, the way we learn about the world and the way we conduct business.”

Ron Wyden



4 billion internet users

Open Access



Plan S
Making full & immediate
Open Access a reality

Plan S
Making full and
immediate
Open Access a
reality

data.europa.eu
The official portal for European data

83 Catalogues 36 Countries 1 340 500 Datasets

English (en) Search site content Search

Data Impact & Studies Training News & Events About

data.europa.eu
The official portal for European data

Search datasets

- Agribusiness, Food & Health
- Economy & Finance
- Education & Sport
- Energy
- Environment
- Government & Public Sector
- Health
- International Issues
- Justice & Legal System
- Population & Society
- Regions & Cities
- Science & Technology
- Transport

Search datasets Search


> TO DATA CATALOGUES > TO ALL DATASETS > EU INSTITUTIONS DATASETS



UNESCO
IN BRIEF WHAT WE DO WHERE WE WORK PARTNERS JOIN US RESOURCES
"Building peace in the minds of men and women"

Home > Open Science > UNESCO Recommendation on Open Science

Open Science



Information v misinformation



World Health Organization (WHO) 
@WHO

False information on #COVID19 is spreading & putting people in danger. Make sure to double-check everything you hear against **trusted sources**. For accurate information on #coronavirus find official advice from your country's public health authority & WHO:
bit.ly/3dFdKdU



0:21 | 122.2K views


We know that Cochrane is a trusted source BUT do people looking for information to inform decisions know about Cochrane, know how to find us and how to use our information?

Increased competition

Number of Cochrane Reviews:



Number of systematic reviews:



Data from PubMed

Types of systematic reviews:

- Intervention
- Diagnostic Test Accuracy
- Methodology
- Qualitative
- Prognosis
- Overviews of systematic reviews
- Living systematic reviews
- Rapid reviews
- Complex health
- Interventions in complex systems

Author experience with Cochrane is important because authors can publish elsewhere.

Authors typically use Cochrane:

- Methods
- Software
- Training

NEWS FLASH

Tomorrow is here!

Is Cochrane still relevant?

Do we get our evidence products to those who need them?

- Potentially 7.8 billion beneficiaries



PUBLIC, PATIENTS,
AND CARERS



HEALTH AND CARE
WORKERS



RESEARCHERS



POLICY AND
GUIDELINE
DEVELOPERS


Are our products fit for purpose?

- Can people understand our information?
- Can they use our information when they get it?
- Is Cochrane simple, agile and able to adapt?

What is our IMPACT?

- What is the primary outcome?
- Can we measure it?

Cochrane community's outstanding response to COVID 19 pandemic



2020 Annual Review

Collaborating in response to COVID-19

- 23 COVID-19 Cochrane systematic reviews
- Rapid reviews, living reviews and living evidence maps
- Stakeholder priority setting, consumer and citizen involvement
- Cochrane COVID-19 Study Register
- 8 COVID-19 Special collections, and other evidence collections
- COVID-19 evidence with unrestricted access and in 13 languages
- Hundreds of social media posts, newsletters, press releases, blogs, journal articles, podcasts, visual summaries, videos, events, and advocacy statements



Our Compass must be:

Clear purpose (Vision and Mission)

Core principles (culture):

- Relevance -meet needs of beneficiaries
- Quality
- Integrity
- Collaborative and inclusive
- Competitive, stimulating and innovative
- Affordable and Sustainable
- Independent and transparent
- Deliver on commitments and promises
- Timely, simple and effective



“If necessity is the mother of invention, then adversity must surely be the father of re-invention.”

Johnny Flora

Cochrane is its people not its structure.

Let's create the future together.

Questions from the Board to the CEO

- Are we focusing on the right activities, or are we doing things that are over and above our core charitable aims? If we are, should we stop doing those things?
- What core activities do we want to sustain under any circumstances?
- Is it possible to diversify or broaden sources of income?



Thank you

Welcome - Judith Brodie – Interim CEO



What's next?

Tracey Howe

Co-Chair, Governing Board

Judith Brodie

Interim Chief Executive Officer

Karla Soares-Weiser

Editor in Chief

Question & Answers

Audience



Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Editorial Independence & Efficiency project: an information and discussion session

Aim: To provide an update about the progress of the Editorial Independence & Efficiency project, and to hear from the Cochrane community on their ideas about models for the future of producing reviews in Cochrane.

Opportunity: To discuss the challenges and benefits associated with the Central Editorial Service pilot and the wider issues relating to producing reviews in Cochrane.

Moderators: Karla Soares-Weiser, Toby Lasserson, Rachel Marshall, Ruth Foxlee, Vanessa Piechotta, Vanessa Jordan, Robert Boyle, Roger Soll, Robert Boyle, Rachel Plachcinski

Cochrane and demonstrating our impact: What data and metrics are useful Promoting to Cochrane Groups and members?

Aim: To understand Cochrane's visibility with external stakeholders and demonstrate the impact and value of our work to support future sustainability.

Opportunity: To discuss how we can increase Cochrane's visibility with external stakeholders and demonstrate value and impact, particularly to decision-makers and funders; results of the session will inform the development of strategic monitoring and evaluation of Cochrane's impact and a sustainable business model.

Moderators: Matteo Bruschettini, Rachel Plachcinski, Denise Thomson, Irena Zakarija-Grkovic, Sylvia De Haan, Juliane Ried

Challenges and opportunities for Open Access to Cochrane Reviews: An information and discussion session

Aim: To provide a detailed update on Cochrane's Open Access strategy plans and introduce Cochrane's proposed 'roadmap' for the development of a sustainable open access model.

Opportunity: Hear about Cochrane's Open Access research and consultation project; and discuss the challenges Cochrane faces in the context of recent policy changes in the OA environment.

Moderators: Chris Champion, Charlotte Pestridge, John Hilton, Rachel Craven, Roger Tritton

Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

What's next?

Tracey Howe

Co-Chair, Governing Board

Judith Brodie

Interim Chief Executive Officer

Karla Soares-Weiser


Editor in Chief

Question & Answers

Audience





Results of polls





What is the biggest challenge Cochrane faces?





What is the biggest opportunity for Cochrane?

• evidence-based healthcare is more important than ever • 50.0% 36 Votes

• Increasing our brand profile and understanding • 6.9% 5 Votes

• Fundraising in new ways • 11.1% 8 Votes

• The resources and talent in our network and communities • 19.4% 14 Votes

• The potential of covering social care as well as healthcare • 8.3% 6 Votes

• More consumer (citizen) involvement • 4.2% 3 Votes

evidence-based healthcare is more important than ever • 38.9% 75 Votes

Increasing our brand profile and understanding • 10.4% 20 Votes

Fundraising in new ways • 15.0% 29 Votes



The resources and talent in our network and communities • 23.8% 46 Votes

The potential of covering social care as well as healthcare • 4.7% 9 Votes

More consumer (citizen) involvement • 7.3% 14 Votes



Who is the most important audience for Cochrane Reviews





BIGGER CHALLENGES FOR REVIEW PRODUCTION WE NEED TO PRIORITIZE

Bespoke tools · 1.5%
1 Votes

Cumbersome system and process · 49.3%
33 Votes

Overwhelming standards · 10.4%
7 Votes

Long format of Cochrane Reviews · 11.9%
8 Votes

52 CRGs producing reviews with
inconsistent standards · 26.9%
18 Votes

Bespoke tools · 5.9%
10 Votes

Cumbersome system and process · 28.4%
48 Votes

Overwhelming standards · 16.0%
27 Votes

Long format of Cochrane Reviews · 14.8%
25 Votes

52 CRGs producing reviews with
inconsistent standards · 34.9%
59 Votes

Running Order

Session:	Duration:
Welcome & Networking	30 minutes
Community Speed Networking	25 minutes
Main Plenary: Cochrane's strategic challenges & opportunities	60 minutes
Comfort Break & Community Speed Networking	15 minutes
Breakout sessions	75 minutes
Main Plenary: What's Next?	15 minutes
Community Speed Networking	15 minutes

Thank you



Challenges and opportunities

Virtual Governance Meetings

22 and 24 June 2021

Trusted evidence.
Informed decisions.
Better health.



Challenges and opportunities

Judith

01 Introduction to Judith

02 Changes and Challenges

03 Opportunities

04 What now?

Karla

05 Future of review production (including Council and Co-Eds feedback)

06 Feedback, urgency and changes needed

07 Communication

Introduction

- I'm Judith Brodie, Cochrane's interim Chief Executive Officer (CEO)
- Excited and privileged to be joining the Cochrane community
- An experienced CEO and interim CEO, used to leading change in organizations
- I have experience of UK and international organizations



Enjoying an Australian brunch!

Changes and challenges (1)

- We're spending more than our income, reducing our reserves – we need to live within our means
- Funding is less secure, and we are committed to open access which will affect our income
- Increased competition, so have to demonstrate our value and impact
- COVID has demonstrated importance of fast response to health challenges – we need to streamline review production

Changes and challenges (2)

- Huge and organic growth has resulted in much complexity – challenge from National Institute for Health Research (NIHR)
- Need to look to what the future may be for information and evidence and anticipate and adapt
- Clarity on strategic priorities to ensure focus on the right things
- A new business model that's affordable and will sustain Cochrane into the future.

POLL

What do you think is the
biggest *challenge*
Cochrane faces?



What do you think is the biggest challenge?

- A: Reducing costs and increasing fundraising and income?
- B: A new way to deliver Open Access affordably?
- C: Demonstrating our value and impact?
- D: Speeding up and streamlining review production?
- E: Communicating our review findings in more accessible ways?
- F: Anticipating new ways of working and using/accessing information?
- G: Being much more focused on priorities?
- H: A new business model?

VOTE NOW!

Opportunities

- Evidence-based healthcare is more important than ever
- Potential for Cochrane's brand to reach new audiences
- Fundraising in new ways - requires investment and payback will take years to flow
- Cochrane's Community, which is formidable – enormous resources and expertise
- To reflect social care as well as healthcare to maintain relevance
- Do more with our increasingly strong Cochrane Consumer Network, to focus on our ultimate beneficiaries.

POLL

**What do you think is the
biggest *opportunity* for
Cochrane?**



What do you think is the biggest opportunity?

- A: Evidence-based healthcare is more important than ever
- B: Increasing our brand profile and understanding
- C: Fundraising in new ways
- D: Resources and talent across our Community
- E: Covering social care as well as healthcare in our reviews
- F: More consumer (patient) involvement

VOTE NOW!

What now?



What now? (1)

The Governing Board and Senior Management Team believe that radical change is needed to ensure we secure a successful future. So we will:

- Adopt a **Strategy for Change** based on the Community consultation from the past year – will be shared with everyone
- Embark on a **Review and Re-organization** across Cochrane to reduce costs and inefficiencies, and seek new and more streamlined ways of working. It will include:
 - A thorough review of the Central Executive staff Team;
 - Work on editorial, systems, processes and publishing processes (*more from Karla later*)

What now? (2)

We will also:

- Invest in fundraising now to generate new income in future years
- Increase and streamline communications to keep our Community connected and provide regular opportunities for feedback
- Make the most of new technologies and ways to share information, so we do more to future-proof Cochrane

Thank you

jbrodie@cochrane.org






The future of review production in Cochrane

A call for action!

Karla Soares-Weiser
Editor in Chief, Cochrane Library

Trusted evidence.
Informed decisions.
Better health.



“Our challenges aren’t new – exacerbations of existing problems”

“Simpler structure is needed”

“Promoting diversity, equity and inclusion within Cochrane”

“How will these changes impact research priority setting, co-production and peer review?”

“Quality is still our unique selling point”

We heard you!

The right balance between:

- Internal (values) and external needs
- Production time and rigour of methods
- Centralized processes to level-up quality and standards and diffused organization to increase reach-out and facilitate contacts
- Voluntary work and professionalism
- Evidence production and knowledge translation
- Complexity of content and ease of use/accessibility.

POLL

What are the *biggest challenges* for review production that Cochrane needs to prioritize?



What do you think?

- A: Bespoke editorial production ‘tools’
- B: Cumbersome system and process
- C: Overwhelming standards
- D: Long format of Cochrane Reviews
- E: 52 CRGs producing reviews with inconsistent standards

VOTE NOW!

Why the sense of urgency?

1. Threat to the current funding model
2. Mandate to adhere to Open Access by 2025
3. Inconsistent review production model
with considerable inefficiencies

Why are changes needed now?

- Highly competitive landscape
- Different types of evidence syntheses needed to respond to end-users. We need to focus on:
 - Priority setting and production of relevant reviews
 - Keep methodological quality standards
 - Produced timely
 - Accessible reviews

What needs to change in the way we produce reviews?

- Tools and processes to develop reviews need to be less cumbersome and fit for purpose for the next decade.
- Consistent editorial and publishing processes and maintain our independence.
- End-to-end author's experience:
 - Long format of reviews
 - Complexity of methods and standards versus capacity-building
 - Inconsistent author's experience

Guiding principles of future changes



Simplicity

Easy to understand and externally focus; able to attract high quality authors



Diversity

Diverse methods, people and products



Collaboration

Build on shared expertise and vision



Efficiency

Produced in a timely fashion

Relevance
Quality
Independence
Integrity



Consistency

Using the same standards

POLL

**In your view, *who* is the
most important
audience for Cochrane
Reviews?**



What do you think?

- A: Researchers
- B: Guideline developers and policy-makers
- C: Consumers of health
- D: Clinicians

VOTE NOW!




Communications

We will communicate regularly and seek feedback

- We will step up our communications and ensure regular updates on these changes
- We will seek your ideas and feedback at key stages

We are in this together
and we know we all want
to see a strong and
successful Cochrane
doing its great work into
the future.



Thank you